In a report released today, Michael Higgins from Ladenburg reiterated a Buy rating on Novus Therapeutics, Inc. (NVUS), with a price target of $10. The company’s shares closed yesterday at $2.22, close to its 52-week low of $1.52.
According to TipRanks.com, Higgins has 0 stars on 0-5 star ranking scale with an average return of -5.0% and a 32.2% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Melinta Therapeutics Inc, and Eiger Biopharmaceuticals.
The the analyst consensus on Novus Therapeutics, Inc. is currently a Hold rating.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.61 and a one-year low of $1.52. Currently, Novus Therapeutics, Inc. has an average volume of 42.19K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novus Therapeutics Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of products for disorders of the ear, nose, and throat. Its product pipelines include OPO201; OP0101; and OP0102. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.
